An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial
Christopher Wood,Pramod Srivastava,Ronald Bukowski,Louis Lacombe,Andrei I Gorelov,Sergei Gorelov,Peter Mulders,Henryk Zielinski,Axel Hoos,Florentina Teofilovici,Leah Isakov,Robert Flanigan,Robert Figlin,Renu Gupta,Bernard Escudier
12–18 July 2008
Copyright © 2008, Elsevier
Welcome to RightsLink
Elsevier has partnered with Copyright Clearance Center's RightsLink service to offer a variety of options for reusing Elsevier content. Select the "I would like to ..." drop-down menu to view the many reuse options available to you.
I would like to...
To request permission for a type of use not listed, please contact Elsevier Global Rights Department.Are you the author of this Elsevier journal article?
Clearance Center, Inc. All Rights Reserved.
Comments? We would like to hear from you. E-mail us at